Oragenics, Inc. To Participate at the 15th Annual Traumatic Brain Injury Conference
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company developing novel intranasal therapies for concussion and other brain-related conditions, announced its participation in the 15th Annual Traumatic Brain Injury Conference.
The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics
UF startup Dialectic Therapeutics, in partnership with the Fibrolamellar Cancer Foundation (FCF), will supply the experimental drug DT2216 for a clinical trial involving fibrolamellar patients.
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
UF Innovate | Accelerate graduate Oragenics announced that it has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee (HDEC) in New Zealand.
Mission Health Communities Enhances Resident Care Through eBrief™ Early Adopter Program
UF Innovate | Accelerate resident client etectRx™ announces its partnership with Mission Health Communities, marking a significant addition to the growing roster of eBrief™ partners.
iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors
UF startup iOncologi announced the acquisition of TargImmune Therapeutics to enhance its capabilities in developing immunotherapies for solid tumors.
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury
UF Innovate | Accelerate graduate Oragenics, Inc. announced the submission of its Investigator’s Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia.
Solid Biosciences Reports Positive Initial Clinical Data From Next-Generation Duchenne Gene Therapy Candidate SGT-003
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced positive initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy candidate for treating Duchenne muscular dystrophy.
LLNL and Canaery Develop Cutting-Edge Neural Interface Technology for Scent Detection
UF Innovate | Accelerate resident client Canaery and LLNL have developed an advanced nose-computer interface (NCI) that enhances scent detection animals’ ability to identify explosives, narcotics, contraband, and biomarkers for neurological and infectious diseases.
A Nose-Computer Interface Could Turn Dogs Into Super Detectors
UF Innovate | Accelerate resident client Canaery is partnering with a US Department of Energy lab to develop neural implants for rats and dogs that are capable of decoding what they smell.
Oragenics, Inc. Announces Partnership With BRAINBox Solutions To Revolutionize Concussion Diagnosis and Treatment
UF Innovate | Accelerate graduate Oragenics, Inc., a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI).